Abstract
Objectives: The aim of this systematic review and meta-analysis is to analyze clinical trials on the use of autologous stem cell [SC] injection for the treatment of stress urinary incontinence [SUI] in humans.
Methods: We analyzed the effect in terms of UI improvement and continence recovery after treatment. A literature search was performed following the PRISMA guidelines. Entry into the analysis was restricted to data collected from clinical prospective trials on humans, including female and male patients with SUI. We performed a cumulative meta-analysis to explore the trend in the effect size across different groups at follow-up. Available data were compared in terms of Event Rate [ER] for the percentage of pad-free patients.
Results: 12 trials were enclosed in the analysis. The sample size of patients with SUI ranged from 5 to 123 cases, mainly female cases. Autologous muscle-derived stem cells [MDSCs] were used in 9 and adipocyte- derived SCs [ADSC] in 3 trials. Considering a random effect model, ER of continence recovery was 0.41 [95%CI 0.29 - 0.54], with similar results between the ADSC [ER, 0.40;95%CI 0.12 – 0.69] and the MDSC group [ER 0.41; 95%CI 0.27-0.55] [I2 84.69%; Q 104.69 - p<0.01] [Test of group differences p=0.96].
Conclusion: Autologous MDSC or ADSC injection to treat SUI is demonstrated to be a safe procedure and a 41% mean rate of continence recovery is described. A higher effort should be produced to design better clinical trials, objectively evaluating either modifications inside the urethral sphincter or long-term functional results in terms of pad test and UI questionnaires.
Keywords: stem cell, muscle derived stem cell, adipose derived stem cell, bone marrow derived stem cell, stress urinary incontinence.
Graphical Abstract
[1]
Sciarra A, Viscuso P, Arditi A, et al. A biofeedback-guided programme or pelvic floor muscle electric stimulation can improve early recovery of urinary continence after radical prostatectomy: A meta-analysis and systematic review. Int J Clin Pract 2021; 75(10): e14208.
[http://dx.doi.org/10.1111/ijcp.14208] [PMID: 33811418]
[http://dx.doi.org/10.1111/ijcp.14208] [PMID: 33811418]
[2]
Klapper-Goldstein H, Tamam S, Sade S, Weintraub AY. A systematic review of stem cell therapy treatment for women suffering from stress urinary incontinence. Int J Gynaecol Obstet 2021; 5: 1-12.
[PMID: 34048059]
[PMID: 34048059]
[3]
Schmid FA, Williams JK, Kessler TM, et al. Treatment of stress urinary incontinence with muscle stem cells and stem cell components: Chances, challenges and future prospects. Int J Mol Sci 2021; 22(8): 3981-93.
[http://dx.doi.org/10.3390/ijms22083981] [PMID: 33921532]
[http://dx.doi.org/10.3390/ijms22083981] [PMID: 33921532]
[4]
Qu-Petersen Z, Deasy B, Jankowski R, et al. Identification of a novel population of muscle stem cells in mice: Potential for muscle regeneration. J Cell Biol 2002; 157(5): 851-64.
[http://dx.doi.org/10.1083/jcb.200108150] [PMID: 12021255]
[http://dx.doi.org/10.1083/jcb.200108150] [PMID: 12021255]
[5]
Corcos J, Loutochin O, Campeau L, et al. Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a rat model of stress urinary incontinence. Neurourol Urodyn 2011; 30(3): 447-55.
[http://dx.doi.org/10.1002/nau.20998] [PMID: 21412824]
[http://dx.doi.org/10.1002/nau.20998] [PMID: 21412824]
[6]
Kinebuchi Y, Aizawa N, Imamura T, Ishizuka O, Igawa Y, Nishizawa O. Autologous bone-marrow-derived mesenchymal stem cell transplantation into injured rat urethral sphincter. Int J Urol 2010; 17(4): 359-68.
[http://dx.doi.org/10.1111/j.1442-2042.2010.02471.x] [PMID: 20202003]
[http://dx.doi.org/10.1111/j.1442-2042.2010.02471.x] [PMID: 20202003]
[7]
Obinata D, Matsumoto T, Sakuma T, et al. Transplantation of mature adipocyte-derived dedifferentiated cells improves urethral sphincter contractility in a rat mode. Int J Urol 2011; 18: 827-34.
[8]
Chermansky CJ, Tarin T, Kwon DD, et al. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology 2004; 63(4): 780-5.
[http://dx.doi.org/10.1016/j.urology.2003.10.035] [PMID: 15072911]
[http://dx.doi.org/10.1016/j.urology.2003.10.035] [PMID: 15072911]
[9]
Kwon D, Kim Y, Pruchnic R, et al. Periurethral cellular injection: Comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology 2006; 68(2): 449-54.
[http://dx.doi.org/10.1016/j.urology.2006.03.040] [PMID: 16904482]
[http://dx.doi.org/10.1016/j.urology.2006.03.040] [PMID: 16904482]
[10]
Lee JY, Cannon TW, Pruchnic R, Fraser MO, Huard J, Chancellor MB. The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2003; 14(1): 31-7.
[http://dx.doi.org/10.1007/s00192-002-1004-5] [PMID: 12601514]
[http://dx.doi.org/10.1007/s00192-002-1004-5] [PMID: 12601514]
[11]
Jalali Tehrani H, Daryabari SS, Fendereski K, Alijani Zirdehi M, Kajbafzadeh AM. Application of adipose-derived, muscle-derived, and co-cultured stem cells for the treatment of stress urinary incontinence in rat models. Low Urin Tract Symptoms 2021; 13(2): 308-18.
[http://dx.doi.org/10.1111/luts.12360] [PMID: 33098273]
[http://dx.doi.org/10.1111/luts.12360] [PMID: 33098273]
[12]
Bilhar APM, Bortolini MAT, Se AB, Feitosa SM, Zanotelli E, Castro RA. Long-term effects of muscle-derived stem cell therapy on the regeneration of the urethral of female rats. Int Urogynecol J Pelvic Floor Dysfunct 2021; 33(4): 965-75.
[http://dx.doi.org/10.1007/s00192-021-04708-y]
[http://dx.doi.org/10.1007/s00192-021-04708-y]
[13]
Higgins JPT, Altman DG. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons 2008; pp. 187-241.
[http://dx.doi.org/10.1002/9780470712184.ch8]
[http://dx.doi.org/10.1002/9780470712184.ch8]
[14]
Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: A randomised controlled trial. Lancet 2007; 369(9580): 2179-86.
[http://dx.doi.org/10.1016/S0140-6736(07)61014-9] [PMID: 17604800]
[http://dx.doi.org/10.1016/S0140-6736(07)61014-9] [PMID: 17604800]
[15]
Aicher WK, Hart ML, Stallkamp J, et al. Towards a treatment of stress urinary incontinence: Application of mesenchymal stromal cells for regeneration of the sphincter muscle. J Clin Med 2014; 3(1): 197-215.
[http://dx.doi.org/10.3390/jcm3010197] [PMID: 26237258]
[http://dx.doi.org/10.3390/jcm3010197] [PMID: 26237258]
[16]
Sèbe P, Doucet C, Cornu JN, et al. Intrasphincteric injections of autologous muscular cells in women with refractory stress urinary incontinence: A prospective study. Int Urogynecol J Pelvic Floor Dysfunct 2011; 22(2): 183-9.
[http://dx.doi.org/10.1007/s00192-010-1255-5] [PMID: 20821309]
[http://dx.doi.org/10.1007/s00192-010-1255-5] [PMID: 20821309]
[17]
Cornu JN, Lizée D, Pinset C, Haab F. Long-term follow-up after regenerative therapy of the urethral sphincter for female stress urinary incontinence. Eur Urol 2014; 65(1): 256-8.
[http://dx.doi.org/10.1016/j.eururo.2013.09.022] [PMID: 24075578]
[http://dx.doi.org/10.1016/j.eururo.2013.09.022] [PMID: 24075578]
[18]
Strasser H, Marksteiner R, Margreiter E, et al. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. World J Urol 2007; 25(4): 385-92.
[http://dx.doi.org/10.1007/s00345-007-0190-7] [PMID: 17701044]
[http://dx.doi.org/10.1007/s00345-007-0190-7] [PMID: 17701044]
[19]
Kuismanen K, Sartoneva R, Haimi S, et al. Autologous adipose stem cells in treatment of female stress urinary incontinence: Results of a pilot study. Stem Cells Transl Med 2014; 3: 936-41.
[http://dx.doi.org/10.5966/sctm.2013-0197]
[http://dx.doi.org/10.5966/sctm.2013-0197]
[20]
Stangel-Wojcikiewicz K, Jarocha D, Piwowar M, et al. Autologous muscle-derived cells for the treatment of female stress urinary incontinence: A 2-year follow-up of a Polish investigation. Neurourol Urodyn 2014; 33(3): 324-30.
[http://dx.doi.org/10.1002/nau.22404] [PMID: 23606303]
[http://dx.doi.org/10.1002/nau.22404] [PMID: 23606303]
[21]
Stangel-Wojcikiewicz K, Piwowar M, Jach R, Majka M, Basta A. Quality of life assessment in female patients 2 and 4 years after muscle-derived cell transplants for stress urinary incontinence treatment. Ginekol Pol 2016; 87(3): 183-9.
[http://dx.doi.org/10.17772/gp/61330] [PMID: 27306126]
[http://dx.doi.org/10.17772/gp/61330] [PMID: 27306126]
[22]
Jankowski RJ, Tu LM, Carlson C, et al. A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. Int Urol Nephrol 2018; 50(12): 2153-65.
[http://dx.doi.org/10.1007/s11255-018-2005-8] [PMID: 30324580]
[http://dx.doi.org/10.1007/s11255-018-2005-8] [PMID: 30324580]
[23]
Yiou R, Hogrel JY, Loche CM, et al. Periurethral skeletal myofiber implantation in patients with urinary incontinence and intrinsic sphincter deficiency: A phase I clinical trial. BJU Int 2013; 111: 1105-16.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11682.x] [PMID: 23470219]
[http://dx.doi.org/10.1111/j.1464-410X.2012.11682.x] [PMID: 23470219]
[24]
Sharifiaghdas F, Tajalli F, Taheri M, et al. Effect of autologous muscle-derived cells in the treatment of urinary incontinence in female patients with intrinsic sphincter deficiency and epispadias: A prospective study. Int J Urol 2016; 23(7): 581-6.
[http://dx.doi.org/10.1111/iju.13097] [PMID: 27062371]
[http://dx.doi.org/10.1111/iju.13097] [PMID: 27062371]
[25]
Mitterberger M, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts for female stress incontinence: A 1-year follow-up in 123 patients. BJU Int 2007; 100(5): 1081-5.
[http://dx.doi.org/10.1111/j.1464-410X.2007.07119.x] [PMID: 17760890]
[http://dx.doi.org/10.1111/j.1464-410X.2007.07119.x] [PMID: 17760890]
[26]
Blaganje M. Lukanović A. Ultrasound-guided autologous myoblast injections into the extrinsic urethral sphincter: Tissue engineering for the treatment of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2013; 24(4): 533-5.
[http://dx.doi.org/10.1007/s00192-012-1963-0] [PMID: 23111866]
[http://dx.doi.org/10.1007/s00192-012-1963-0] [PMID: 23111866]
[27]
Carr LK, Robert M, Kultgen PL, et al. Autologous muscle derived cell therapy for stress urinary incontinence: A prospective, dose ranging study. J Urol 2013; 189(2): 595-601.
[http://dx.doi.org/10.1016/j.juro.2012.09.028] [PMID: 23260547]
[http://dx.doi.org/10.1016/j.juro.2012.09.028] [PMID: 23260547]
[28]
Arjmand B, Pourmand G. Concomitant transurethral and transvaginal periurethral injection of autologous adipose derived stem cells for treatment of female stress urinary incontinence: a phase one clinical trial. Acta Med Iran 2017; 55(6): 368-74.
[29]
Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol 2014; 192(2): 469-76.
[http://dx.doi.org/10.1016/j.juro.2014.02.047] [PMID: 24582537]
[http://dx.doi.org/10.1016/j.juro.2014.02.047] [PMID: 24582537]
[30]
Gotoh M, Yamamoto T, Shimizu S, et al. Treatment of male stress urinary incontinence using autologous adipose-derived regenerative cells: Long-term efficacy and safety. Int J Urol 2019; 26(3): 400-5.
[http://dx.doi.org/10.1111/iju.13886] [PMID: 30557919]
[http://dx.doi.org/10.1111/iju.13886] [PMID: 30557919]
Article Metrics
3